News
Delighted to have been part of ISPOR conference 2023!
Delighted to have been part of ISPOR—The Professional Society for Health Economics and Outcomes Research in #copenhagen ! Presenting 10 #posters was a highlight, especially with one making it to the top 5%. 🏆 Once again, it was an excellent #ISPOREurope! Thanks to all...
Health Through Evidence will be participating in the upcoming ISPOR – Europe 2023 conference!
We are excited to announce that Health Through Evidence will be participating in the upcoming ISPOR – International Society for Pharmaceutical Outcomes Research – Europe 2023 conference, to be held in Copenhagen between November 13th and 15th. Health Through Evidence...
Publication Alert: 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
Happy to share our latest publication " Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece". Happy to share our most recent, open-access publication " Health and...
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
Happy to share our latest publication about the potential health and economic impact of switching the current 13-valent Pneumococcal Conjugate Vaccine (PCV13) among the Greek paediatric Vaccination programme with higher-valent conjugate vaccines. Find out more at:...
8th Annual HTA Conference
"Health Through Evidence had the pleasure of sponsoring the '8th Annual HTA Conference,' which was held on June 14th in Athens, organized by BOUSSIAS and Health Daily. The main theme of the 2023 HTA conference was the new role that HTA and Νegotiations are called upon...